{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260825861058/en/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Advanced-Biliary-Tract-Cancer-in-Single-Region-Trial-Conducted-by-Akeso-in-China", "message": "News view counter 902343 successfully enlarged"}